We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

128 hedge funds and large institutions have $335M invested in Progenics Pharmaceuticals Inc in 2019 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 44 increasing their positions, 35 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 35

2% less capital invested

Capital invested by funds: $343M → $335M (-$8.12M)

5% less funds holding

Funds holding: 135 → 128 (-7)

27% less call options, than puts

Call options by funds: $1.01M | Put options by funds: $1.38M

28% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 25

Holders
128
Holders Change
-7
Holders Change %
-5.19%
% of All Funds
2.52%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
18
Increased
44
Reduced
35
Closed
25
Calls
$1.01M
Puts
$1.38M
Net Calls
-$367K
Net Calls Change
-$1.64M

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$7.81M
2
AA
AQR Arbitrage
Connecticut
+$5.59M
3
FCM
Farallon Capital Management
California
+$4.76M
4
State Street
State Street
Massachusetts
+$3.86M
5
BlackRock
BlackRock
New York
+$3M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$14.1M
2
RHJA
Rice Hall James & Associates
California
-$8.98M
3
PA
Pinnacle Associates
New York
-$6.43M
4
PFC
Phocas Financial Corp
California
-$5.17M
5
RA
Royce & Associates
New York
-$4.93M
Name Holding Trade Value Shares
Change 		Change in
Stake
PFBT
126
Parkside Financial Bank & Trust
Missouri
$1K – – –
RMAM
127
Raab & Moskowitz Asset Management
New Jersey
$1K +$1.06K +200 New
Point72 Asset Management
128
Point72 Asset Management
Connecticut
– -$14.1M -2,785,100 Closed
RHJA
129
Rice Hall James & Associates
California
– -$8.98M -1,776,490 Closed
PFC
130
Phocas Financial Corp
California
– -$5.17M -1,022,708 Closed
RA
131
Royce & Associates
New York
– -$4.93M -974,439 Closed
JGC
132
J. Goldman & Co
New York
– -$2.53M -499,698 Closed
AA
133
ALPS Advisors
Colorado
– -$871K -172,337 Closed
MCM
134
Moore Capital Management
New York
– -$632K -125,000 Closed
HKAM
135
Horizon Kinetics Asset Management
New York
– -$340K -67,200 Closed
Stifel Financial
136
Stifel Financial
Missouri
– -$196K -38,916 Closed
WVP
137
Worth Venture Partners
New Jersey
– -$167K -32,956 Closed
JMPWA
138
JP Morgan Private Wealth Advisors
California
– -$154K -30,442 Closed
Millennium Management
139
Millennium Management
New York
– -$115K -22,858 Closed
DekaBank Deutsche Girozentrale
140
DekaBank Deutsche Girozentrale
Germany
– -$113K -21,500 Closed
Creative Planning
141
Creative Planning
Kansas
– -$101K -19,900 Closed
Citadel Advisors
142
Citadel Advisors
Florida
– -$91K -17,198 Closed
Victory Capital Management
143
Victory Capital Management
Texas
– -$60K -11,902 Closed
PI
144
PineBridge Investments
New York
– -$53K -10,396 Closed
QT
145
Quantbot Technologies
New York
– -$42K -8,412 Closed
GT
146
Glenmede Trust
Pennsylvania
– -$41 -8,262 Closed
IWA
147
Intercontinental Wealth Advisors
Texas
– -$29K -5,725 Closed
AAMU
148
Amundi Asset Management US
Massachusetts
– -$12K -2,454 Closed
EW
149
Evoke Wealth
California
– -$5.32K -1,052 Closed
FCMT
150
Founders Capital Management (Texas)
Texas
– -$5K -1,000 Closed
3 4 5
6
7

PGNX Hedge Fund Activity: Q4 2019 in Review

128 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q4 2019, worth a combined $335M — down 2.4% from $343M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of PGNX and 18 opened new positions — a net loss of 7 holders — while 35 trimmed existing stakes and 44 added.

The largest buyer was Broadfin Capital, adding an estimated $7.81M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $14.1M sold.

  • 128 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q4 2019, down from 135 in Q3 2019.
  • Funds reported $335M of Progenics Pharmaceuticals Inc stock for Q4 2019, down 2.4% quarter-over-quarter.
  • 18 funds opened new Progenics Pharmaceuticals Inc positions in Q4 2019 and 25 closed out, a net change of -7 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q4 2019 was Broadfin Capital, an estimated $7.81M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q4 2019 was Point72 Asset Management, an estimated $14.1M sold.

Based on aggregated 13F filings for Q4 2019.